LYRA - Lyra Therapeutics, Inc.
0.0995
-0.005 -5.528%
Share volume: 1,376,502
Last Updated: 04-28-2025
Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies:
1.01%
PREVIOUS CLOSE
CHG
CHG%
$0.10
-0.01
-0.05%
Fundamental analysis
24%
Profitability
0%
Dept financing
5%
Liquidity
50%
Performance
45%
Performance
5 Days
0.40%
1 Month
-21.22%
3 Months
-45.42%
6 Months
-62.47%
1 Year
-97.90%
2 Year
-96.16%
Key data
Stock price
$0.10
DAY RANGE
$0.10 - $0.11
52 WEEK RANGE
$0.08 - $5.65
52 WEEK CHANGE
-$98.07
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
Company detail
CEO: Maria Palasis
Region: US
Website: lyratherapeutics.com
Employees: 50
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing
Region: US
Website: lyratherapeutics.com
Employees: 50
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Medical Equipment/Surgical, Medical, And Dental Instruments And Supplies
Sector: Manufacturing
Lyra Therapeutics, Inc. focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial.
Recent news
